Colleen Kelley
Overview
Dr. Kelley is a faculty member in the Division of Infectious Diseases with a secondary appointment in the Department of Epidemiology, Rollins School of Public Health. She graduated from Emory University with her MD/MPH degree and completed her Internal Medicine residency at the University of California San Francisco and Infectious Diseases fellowship at Emory University.
Dr. Kelley has a multi-disciplinary background and previous clinical and research experience in HIV medicine, HIV epidemiology and clinical outcomes research, and laboratory-based HIV research. She sees outpatients at the Grady Infectious Disease Program and inpatients on the Infectious Diseases consult service and Special Immunology Service at Grady Memorial Hospital.
The current focus of her research is on biomedical HIV prevention interventions including pre and post-exposure prophylaxis (PrEP and PEP) and HIV vaccines. She conducts translational immunology studies of HIV susceptibility in men who have sex with men (MSM) to better understand rectal HIV transmission. Dr Kelley is a site investigator for the HIV Vaccine Trials Network at the Hope Clinic and also collaborates closely with colleagues in the School of Public Health on several HIV prevention studies including PrEP implementation projects.
Academic Appointment
- Professor of Medicine, Emory School of Medicine
- Associate Professor of Medcine, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine
- Senior Physician, Emory University School of Medicine
- Assistant Professor of Epidemiology, Department of Epidemiology, Rollins School of Public Health
Education
Degrees
- BA from University of Florida
- MD/MPH from Emory University School of Medicine
Research
Focus
- The focus of my research is HIV transmission in men who have sex with men with a recent focus on the biologic mechanisms of the disparity in HIV incidence between black and white men. In addition, I am also interested in exploring how the efficacy of biomedical HIV prevention interventions may be maximized for high-risk MSM. My approach to answer these questions generally involves translational immunology studies. I aspire to an independently funded academic research career with a focus on HIV prevention science.
Publications
-
Preventing Premature Pre-Exposure Prophylaxis Discontinuation and Sexually Transmitted Infections Among Men Who Have Sex With Men (Project PEACH): Protocol for a Prospective Cohort Study.
JMIR Res Protoc Volume: 14 Page(s): e56096
04/23/2025 Authors: Aldredge A; Carter D; DeCree CA; Gardner EV; Herring GB; Kaabi O; Moges-Banks R; Valencia R; Kelley CF; Sullivan PS -
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.
J Infect Dis Volume: 231 Page(s): e764 - e769
04/15/2025 Authors: Wilson GJ; Church LWP; Kelley CF; Robinson ST; Lu Y; Furch BD; Fong Y; Paez CA; Yacovone M; Jacobsen T -
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
N Engl J Med Volume: 392 Page(s): 1261 - 1276
04/03/2025 Authors: Kelley CF; Acevedo-Quiones M; Agwu AL; Avihingsanon A; Benson P; Blumenthal J; Brinson C; Brites C; Cahn P; Cantos VD -
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.
Clin Infect Dis
01/28/2025 Authors: Marcus JL; Weddle A; Kelley CF; Agwu A; Montalvo S; Sherman E; Vijayan T; Gutierrez J; Hickey MD; Dilworth SE -
Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome.
Nat Med Volume: 31 Page(s): 207 - 217
01/01/2025 Authors: Chu VT; Glascock A; Donnell D; Grabow C; Brown CE; Ward R; Love C; Kalantar KL; Cohen SE; Cannon C -
Rectal mucosal inflammation, microbiome, and wound healing in men who have sex with men who engage in receptive anal intercourse.
Sci Rep Volume: 14 Page(s): 31598
12/30/2024 Authors: Van Doren VE; Ackerley CG; Arthur RA; Murray PM; Smith SA; Hu Y-J; Kelley CF -
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.
Open Forum Infect Dis Volume: 11 Page(s): ofae689
12/01/2024 Authors: Follmann D; Wang X; Baden LR; El Sahly HM; Essink B; Gilbert P; Janes HE; Kelley CF; Berman MA; Frank I -
Integrated analysis of rectal mucosal microbiome and transcriptome reveals a distinct microenvironment among young MSM.
JCI Insight Volume: 9
11/08/2024 Authors: Ackerley CG; Smith SA; Murray PM; Amancha PK; Van Doren VE; Tharp GK; Arthur RA; Amara RR; Hu Y-J; Kelley CF -
Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials.
Open Forum Infect Dis Volume: 11 Page(s): ofae387
07/01/2024 Authors: Cantos VD; Neradilek M; Huang Y; Roxby AC; Gillespie K; deCamp AC; Karuna ST; Edupuganti S; Gallardo-Cartagena J; Sanchez J -
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
PLoS Med Volume: 21 Page(s): e1004329
06/01/2024 Authors: Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C